| Date | Title | Description |
| 10.09.2024 | Ten medtech startups selected for the Boston roadshow |
A jury of professional investors and Medtech experts reviewed 60 applications to select this year’s Swiss National Team for Venture Leaders Medtech. The one-week business development roadshow to Boston – the world’s major life sciences hub... |
| 26.06.2024 | Revolutionizing Cancer Treatment: Calico Biosystems Leads the Way | Calico Biosystems, a Swiss medtech company, is making waves in the cancer treatment industry with its innovative approach to predicting drug efficacy in cancer patients. With a recent funding boost of CHF 150,000 from Venture Kick, the comp... |
| 25.06.2024 | Calico Biosystems raises €156K for anti-cancer drug development | Swiss medtech company Calico Biosystems has raised CHF 150,000 (€156,000) in funding from Venture Kick.
The company is dedicated to enhancing the clinical efficacy of anti-cancer drugs during the pre-clinical stage in response to the high f... |
| 25.06.2024 | CHF 150,000 for higher cancer drug efficacy |
The poor efficacy of cancer drugs in female patients is the cause of one in six cancer deaths in women. This is mainly due to the fact that the artificial models currently used to test the efficacy of cancer drugs cannot replicate the comp... |
| 25.06.2024 | Calico Biosystems gets the CHF 150,000 Kick to predict drug efficacy in cancer patients | The high failure rate of therapeutics, amounting to over 95%, and the limited patient response to approved cancer treatments highlight the urgent need for an advance in therapeutic testing. Calico Biosystems combines experimental and digita... |
| 14.05.2024 | Two Swiss startups selected for Tech4Eva |
Currently, 77 startups have undergone the Tech4Eva accelerator program, a joint program between EPFL Innovation Park and Groupe Mutuel aiming to accelerate innovations for women’s health, in a market estimated at USD 25 billion. Besides pr... |
| 21.12.2023 | CHF 40,000 for tumor therapies with AI modeling, streamlined legislative analysis for public affairs, and disruptive radio frequency testing | Calico Biosystems: Predicting drug efficacy for cancer patients
Both the high attrition rate (> 95%) of therapeutics and the low response rate of patients to approved anti-cancer therapies call for a game changer in therapeutic testing. ... |
| 25.09.2023 | Startups assessing tumour therapies with AI modelling, streamlining legislative analysis for public affairs, providing disruptive radio frequency testing, enhancing patient care with digital solutions... | Calico Biosystems: Precision Oncology become true for all patients
Both the high attrition rate (> 95%) of therapeutics and the low response rate of patients to approved anti-cancer therapies call for a game changer in therapeutic testin... |
